Open Access Highly Accessed Study protocol

Rationale and design of DECISION: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer

Marcia S Brose*, Christopher M Nutting, Steven I Sherman, Young Kee Shong, Johannes WA Smit, Gerhard Reike, John Chung, Joachim Kalmus, Christian Kappeler and Martin Schlumberger*

BMC Cancer 2011, 11:349  doi:10.1186/1471-2407-11-349

Article Metrics

8935
Total accesses


2
BioMed Central citations

Article metric FAQ

Accesses  

  • Last 30 days: 832 accesses
  • Last 365 days: 3488 accesses
  • All time: 8935 accesses

These numbers are accesses on BioMed Central websites only, and an underestimate of total usage. More information

Cited by

BioMed Central: 2 citations